We serve Chemical Name:2-(HYDROXYMETHYL)ANTHRAQUINONE CAS:17241-59-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(HYDROXYMETHYL)ANTHRAQUINONE
CAS.NO:17241-59-7
Synonyms:9,10-Anthracenedione, 2-(hydroxymethyl)-;2-(Hydroxymethyl)-9,10-anthraquinone;2-(hydroxymethyl)anthracene-9,10-dione;EINECS 241-274-3;MFCD00001236;2-(HYDROXYMETHYL)ANTHRAQUINONE;2-Hydroxy methyl anthraquinone
Molecular Formula:C15H10O3
Molecular Weight:238.238
HS Code:2914690090
Physical and Chemical Properties:
Melting point:192-197 °C(lit.)
Boiling point:472.9±34.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.677
PSA:54.37000
Exact Mass:238.062988
LogP:2.20
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 9,10-Anthracenedione, 2-(hydroxymethyl)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Hydroxy methyl anthraquinone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 241-274-3 Use and application,MFCD00001236 technical grade,usp/ep/jp grade.
Related News: The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. 2-(HYDROXYMETHYL)ANTHRAQUINONE manufacturer This means that the drug attributes of the drug substance will be lost in the future, and the monopoly power of some drug substances will also be lost. The preparation company will become the main person in charge of the drug. The drug preparation company will be responsible for the quality of the original excipients. It will be more cautious, some raw and auxiliary materials companies whose quality cannot be guaranteed will be gradually eliminated, and the industry concentration will be further improved. 2-(HYDROXYMETHYL)ANTHRAQUINONE supplier The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 2-(HYDROXYMETHYL)ANTHRAQUINONE vendor The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. 2-(HYDROXYMETHYL)ANTHRAQUINONE factory The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease.
